PharmaShots | Incisive News in 3 Shots

Subscribe Now

Conditional Approval

$BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma$

BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma

August 20, 2021

$BeiGene's Kyprolis (carfilzomib) Receives NMPA's Conditional Approval for the Treatment of Relapsed or Refractory Multiple Myeloma$

BeiGene's Kyprolis (carfilzomib) Receives NMPA's Conditional Approval for the Treatment of Relapsed or Refractory Multiple Myeloma

July 9, 2021

AveXis Receives EC's Conditional Approval and Activates “Day One” Access Program for Zolgensma (onasemnogene abeparvovec) to Treat Spinal Muscular Atrophy

AveXis Receives EC's Conditional Approval and Activates “Day One” Access Program for Zolgensma (onasemnogene abeparvovec) to Treat...

May 20, 2020

Merck's Ervebo [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Receives EC's Conditional Approval to Prevent Ebola Virus Disease

Merck's Ervebo [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Receives EC's Conditional Approval to Prevent Ebola Virus Disease

November 12, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us